Evolving Therapy for Helicobacter pylori Infection: Efficacy and Economic Impact in the Treatment of Patients with Duodenal Ulcer Disease

American Journal of Managed Care

Volumn 3, Issue 10, 1997, Pages 1528-1534

  Cutler, Alan F ^a   Vakil, Nimish ^b  

^a SINAI GRACE HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COMBINATION; DUODENUM ULCER; ECONOMICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; TREATMENT OUTCOME;

EID: 0031244588     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Howden CW. Clinical expressions of Helicobacter pylori infection. Am J Med 1996;100(suppl):27S-34S.
2. Logan RPH, Bardhan KD, Celestin CR, et al. Eradication of H. pylori and prevention of recurrence of duodenal ulcer: A randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995;9:417-423.
3. Hunt R, Schwartz H, Fitch D, et al. Dual therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with H. pylori infection. Gut 1995;37(suppl 1):A5. Abstract.
4. Bardhan KD, Graham DY, Hunt RH, O'Morain C. Effects of smoking on cure of H. pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997;2:27-31.
5. Bardhan KD, Dallaire C, Eisold H, Duggan AE. GR122311X (ranitidine bismuth citrate) with clarithromycin for the treatment of duodenal ulcer. Gastroenterology 1995;108:A53. Abstract.
6. Pounder RE, Bailey R, Louw JA, et al. GR122311X (raniditine bismuth citrate) with clarithromycin for the eradication of Helicobacter pylori. Gut 1995;37(suppl 1):A5. Abstract.
7. Peterson WL, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-261.
8. Bazzoli F, Zagari MR, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-777.
9. Lamouliatte H, Cayla R, Talbi P, et al. Randomised study comparing two seven day triple therapies with lansoprazole and low dose clarithromycin plus amoxicillin or tinidazole for Helicobacter pylori eradication. Gastroenterology 1996;110:A648. Abstract.
10. Lind T, Veldhuyzen van Zanten SJP, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study. Helicobacter 1996;1:138-144.
11. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996;10:1029-1033.
12. Katicic M, Presecki V, Marusic M, et al. Eradication of H. pylori infection with five different drug regimes. Gut 1996;39(suppl 2):A36. Abstract.
13. Wurzer H, Rodrigo A, Archambault A, et al. Short-course treatment with amoxicillin-clarithromycin triple for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Gut 1996;39(suppl 2):A38. Abstract.
14. Schwartz H, Krause R, Sahba B. Triple vs. dual therapy with lansoprazole, clarithromycin, and/or amoxicillin in the eradication of Helicobacter pylori. Am J Gastroenterol 1996;91:2047. Abstract.
15. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995;155: 922-928.
16. O'Brien B, Goeree R, Mohamed H, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995;155:1958-1964.
17. Imperiale TF, Speroff T, Cebul RD, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995;123:665-672.
18. Vakil N, Fennerty MB. Economic modeling of medical therapy for Helicobacter pylori related peptic ulcer disease. Am J Gastroenterol 1996;91:239-245.
19. Jonsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996;31(suppl 215):90-95.
20. Sonnenberg A, The Gastrointestinal Utilization Trial Study Group. Cost-impact of clarithromycin plus omeprazole compared to traditional therapies for treatment of H. pylori associated duodenal ulcers. Gut 1996;39(suppl 2):A2. Abstract.
21. Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol. 1996;31(suppl 215):74-81.
22. Megraud F. Helicobacter pylori resistance to antibiotics. In: RH Hunt, GNJ Tytgat, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers; 1994:570-583.
23. Banatvala N, Davies G, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to East London: Relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994;35:1562-1566.
24. Witteman EM, Hopman WPM, Becx MCJM, et al. Short report: Smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis. Aliment Pharmacol Ther 1993;7:683-687.
25. Lowy A, Dworkin B, Van Horn K, et al. Clinical and endoscopic characteristics of metronidazole resistant Helicobacter pylori. Gut 1995;37(suppl 1):A72. Abstract.
26. Reddy R, Osato M, Gutierrez O, et al. Metronidazole resistance is high in Korea and Columbia and appears to be rapidly increasing in the US. Gastroenterology 1996;110: A238. Abstract.
27. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-496.
28. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-509.
29. Fallone CA, Barkun AN, Loo V, et al. Compliance, selection of treatment and the absence of duodenitis are predictors of successful eradication of Helicobacter pylori. Gastroenterology 1995;108:A91. Abstract.
30. Penston JG. Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-389.
31. Horwitz R, Horwitz S. Adherence to treatment and health outcomes. Arch Intern Med 1993;153:1863-1868.
32. Chiba N, Rao BV, Rademaker JW, Hunt RH. Metaanalysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87: 1716-1727.
33. Peterson WL, Graham DY, Marshall BJ, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. Am J Gastroenterol 1993;88:1860-1864.
34. Hunt RH. pH and Hpgastric acid secretion and Helicobacter pylori: Implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993;88: 481-483.
35. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med 1996;100(suppl):42S-51S.
36. Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993;5:321-325.
37. Labenz J, Gyenes E, Ruhl GH, Borsch G. Omeprazole plus amoxicillin: Efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol 1993;88:491-495.
38. Bayerdorffer E, Mannes GA, Sommer A, et al. Long term follow up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol 1993;196(suppl):19-25.
39. Axon ATR, Moayyedi P. Eradication of Helicobacter pylori: Omeprazole in combination with antibiotics. Scand J Gastroenterol 1996;31(suppl 215):82-89.
40. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Scand J Gastroenterol 1994;29:1070-1075.
41. Zala G, Schwery ST, Flury R, et al. The negative influence of smoking on H. pylori eradication depends on the therapy regimen. Gastroenterology 1995;108:A266. Abstract.
42. Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39:2078-2083.
43. Bardhan KD, Wurzer H, Marcelino M, et al. High cure rates with ranitidine bismuth citrate (Pylorid) plus clarithromycin given twice daily. Gut 1996;39(suppl 2):A36. Abstract.
44. Craft JC, Olson C, Siepman N, Edmonds A. Clarithromycin resistance in US and European patients treated with clarithromycin and omeprazole for duodenal ulcer disease associated with H. pylori infection. Am J Gastroenterol 1995;90:1579. Abstract.
45. Megraud F, Camou-Juncas C, Occhialini A, Birac C. Helicobacter pylori resistance levels to clarithromycin remain stable. Gastroenterology 1996;10:A983. Abstract.
46. Xia HX, Keane CT, O'Morain CA. A 5-year survey of metronidazole and clarithromycin resistance in clinical isolates of Helicobacter pylori. Gut 1996;39(suppl 2):A6. Abstract.
47. DeKoster E, Cozzoli A, Jonas C, et al. Six years resistance of Helicobacter pylori to macrolides and imidazoles. Gut 1996;39(suppl 2):A5. Abstract.
48. Deltenre M, Jonas C, Burette A, et al. Bazzoli-like schemes are not optimal treatment for HP eradication in Brussels, Belgium. Gastroenterology 1996;110:A977. Abstract.
49. 13C-urea breath tests in assessment of eradication? Gut 1996;39(suppl 2):A118. Abstract.
50. Graham DY, Karttunen TJ, Genta RM. The evaluation of treatment of H. pylori infections: Strategies for the design of clinical trials. Endoscopia Digestiva 1994;6:991-1006.
51. Rubin RJ, Casade EF, Peura DA, et al. Diagnosis and eradication of Helicobacter pylori in the management of peptic ulcer disease: A decision analysis model. Am J Man Care 1996;2:375-383.
52. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-769.
53. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;345:1591-1594.